

Special Issue

Anticancer Research: Towards an Understanding of Cancer and Discovery of New Therapeutic Agents

Message from the Guest Editors

Cancer is one of the main causes of death worldwide. Over recent decades, advances in chemotherapy, targeted therapy, and immunotherapy have improved the prognosis of cancer patients significantly. The problem with treating cancer is that there are more than 200 different cancers resulting from different cellular defects and they often respond to therapeutic agents differently. The development of multidrug resistance and brain metastasis in cancer patients further complicates treatment. In this Special Issue, we welcome reviews and original research on various aspects of cancer, including the identification of novel natural/synthetic compounds with anticancer activity; the design of targeted therapeutic agents; the development of reversal agents for resistant cancer cells; and the design of agents/probes that elucidate mechanisms of action.

Guest Editors

Dr. Yu-shan Wu

Department of Chemistry, Tunghai University, Taichung, Taiwan

Dr. Guor-Jien Wei

Institute of Food Safety and Health Risk Assessment, National Yang Ming Chiao Tung University, Taipei, Taiwan

Deadline for manuscript submissions

closed (30 November 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/111409

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).